The trial met its primary objectives, showing the pill’s effectiveness in helping patients with Type 2 diabetes achieve ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

Eli Lilly shares are now positive for the year, up 10% since the start of January.

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

We recently published a list of 15 Best Blue Chip Stocks to Buy According to Billionaires. In this article, we are going to ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

In an exclusive interview with NBC News' Stephanie Gosk, Eli Lilly's chief scientific officer says their weight loss pills ...

The results bring Eli Lilly's pill orforglipron one step closer to becoming a new, needle-free alternative in the booming ...

Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing ...

The first GLP-1 pill could be in medicine cabinets sooner than expected. Eli Lilly (LLY) announced Thursday that its daily ...